Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to explore the effects of darifenacin in patients with
multiple sclerosis and neurogenic detrusor overactivity. The efficacy, safety and
tolerability of darifenacin are already well established in idiopathic detrusor overactivity.
Patients with multiple sclerosis and neurogenic detrusor overactivity without
detrusor-sphincter-dyssynergia (DSD) will be allocated to darifenacin therapy.